Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
92 hedge funds and large institutions have $338M invested in Chinook Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 17 closing their positions.
142% more call options, than puts
Call options by funds: $577K | Put options by funds: $238K
24% more capital invested
Capital invested by funds: $273M → $338M (+$64.8M)
6% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
2% less funds holding
Funds holding: 94 → 92 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.64M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.97M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$19.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.18M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.15M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.11M |
| 5 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$1.05M |
KDNY Hedge Fund Activity: Q1 2018 in Review
92 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2018, worth a combined $338M — up 24% from $273M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KDNY and 16 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 33 added.
The largest buyer was Millennium Management, adding an estimated $7.2M. The largest seller was Harvard Management Company, cutting an estimated $19.7M.
- 92 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2018, down from 94 in Q4 2017.
- Funds reported $338M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2018, up 24% quarter-over-quarter.
- 16 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2018 and 17 closed out, a net change of -1 holder.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2018 was Millennium Management, an estimated $7.2M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2018 was Harvard Management Company, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2018.